Q1 EPS Forecast for Y-mAbs Therapeutics Reduced by Analyst (2025)

Posted by Defense World Staff on Apr 26th, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) – Stock analysts at Brookline Capital Management dropped their Q1 2025 EPS estimates for Y-mAbs Therapeutics in a note issued to investors on Tuesday, April 22nd. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.22) for the quarter, down from their previous estimate of ($0.17). The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share. Brookline Capital Management also issued estimates for Y-mAbs Therapeutics’ Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.93) EPS.

A number of other equities analysts have also weighed in on the company. Bank of America lowered Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price objective on the stock. in a research note on Tuesday. Truist Financial reduced their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Wedbush reissued an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. HC Wainwright reduced their price target on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Finally, Morgan Stanley decreased their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $17.40.

Read Our Latest Report on Y-mAbs Therapeutics

Y-mAbs Therapeutics Trading Down 0.7 %

YMAB opened at $4.10 on Friday. Y-mAbs Therapeutics has a twelve month low of $3.84 and a twelve month high of $17.78. The firm has a market capitalization of $185.39 million, a PE ratio of -7.59 and a beta of 0.71. The firm’s 50-day moving average price is $4.87 and its 200 day moving average price is $8.19.

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $26.50 million during the quarter, compared to analyst estimates of $26.70 million. During the same period in the prior year, the firm earned ($0.02) earnings per share.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of YMAB. Barclays PLC grew its holdings in Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock worth $910,000 after acquiring an additional 56,244 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after purchasing an additional 47,846 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Y-mAbs Therapeutics in the third quarter valued at $267,000. JPMorgan Chase & Co. lifted its holdings in Y-mAbs Therapeutics by 10.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after buying an additional 2,854 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Y-mAbs Therapeutics by 1.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock worth $2,228,000 after acquiring an additional 4,963 shares in the last quarter. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This trade represents a 5.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 22.50% of the stock is currently owned by company insiders.

About Y-mAbs Therapeutics

(Get Free Report)

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.